EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Therapeutic Repositioning of Antidiabetic Drugs in Dermatology: Biguanides, Incretin-Based Therapies, and PPARγ Agonists in Cutaneous Disease Processes

Yalguunsanaa Erdenekhuu, Jintae Kim, Sung Joon Kim

Pharmaceuticals · 06.11.2026 · 19 (11) · 1764

DOI: 10.3390/ph19111764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 06.11.2026. Verfasst von Yalguunsanaa Erdenekhuu und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bumsuk Academic Research Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic regulation has emerged as a central determinant of skin homeostasis, connecting inflammation, barrier function, tissue repair, aging, fibrosis, and tumorigenesis through altered cellular bioenergetics and stress signaling. Three antidiabetic drug classes have consequently attracted interest as metabolic-targeting strategies in dermatology: biguanides, incretin-based therapies, and peroxisome proliferator-activated receptor gamma (PPARγ) agonists. This review synthesizes the preclinical and emerging clinical literature for each class. We propose an evidence-informed, unvalidated framework that relates these classes to overlapping processes in skin pathology. Biguanides, chiefly metformin, act broadly on inflammatory and proliferative signaling, oxidative stress, and cutaneous tumor biology; their reported effects vary across experimental settings that differ in exposure and delivery. Incretin-based therapies, comprising glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have been investigated in regenerative repair, particularly diabetic wound healing, angiogenesis, epithelialization, and, through DPP-4 (CD26) inhibition, antifibrotic dermal remodeling. PPARγ agonists are most closely tied to epidermal differentiation, barrier and lipid homeostasis, and suppression of fibroblast activation, with additional signals in inflammatory dermatoses, pigmentary disorders, and malignancy. In all three classes, local and topical delivery may influence efficacy, making formulation an important variable for translational evaluation. Because the evidence remains largely preclinical, heterogeneous, and rarely comparative, we propose that metabolic therapies be positioned according to the dominant biologic defect of each dermatologic condition (inflammatory or proliferative dysregulation, regenerative failure, or differentiation and fibrotic remodeling) rather than applied uniformly across skin disease.

Förderung

  • Bumsuk Academic Research Fund

Zitieren

APA

Erdenekhuu, Y., Kim, J., & Kim, S. J. (2026). Therapeutic Repositioning of Antidiabetic Drugs in Dermatology: Biguanides, Incretin-Based Therapies, and PPARγ Agonists in Cutaneous Disease Processes. Pharmaceuticals, 19(11), 1764. https://doi.org/10.3390/ph19111764

Vancouver

Erdenekhuu Y, Kim J, Kim SJ. Therapeutic Repositioning of Antidiabetic Drugs in Dermatology: Biguanides, Incretin-Based Therapies, and PPARγ Agonists in Cutaneous Disease Processes. Pharmaceuticals. 2026;19(11):1764. doi:10.3390/ph19111764

BibTeX
@article{Erdenekhuu2026,
  author = {Erdenekhuu, Yalguunsanaa and Kim, Jintae and Kim, Sung Joon},
  title = {Therapeutic Repositioning of Antidiabetic Drugs in Dermatology: Biguanides, Incretin-Based Therapies, and PPARγ Agonists in Cutaneous Disease Processes},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1764},
  doi = {10.3390/ph19111764}
}
Kostenlos starten →